Optimi Health appoints Parisa Zamiri as CMO, Tom Reilly as CFO

Opthea (OPTHF) announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. Parisa Zamiri, MD, PhD has been appointed Chief Medical Officer, effective October 7, 2024, reporting to Frederic Guerard, PharmD, CEO, Opthea. She will oversee clinical development and operations, regulatory and medical affairs, as well as biometrics. She most recently served as the CMO at Complement Therapeutics. Tom Reilly has been appointed CFO, effective October 28, 2024, reporting to Frederic Guerard.Before joining Opthea, Mr. Reilly served as CFO and Head of Human Resources of Amarin Corporation (AMRN), supporting the commercial expansion of the company’s lead asset in cardiovascular disease. Anand Sundaram has been appointed Vice President Marketing, effective October 14, 2024, reporting to Mike Campbell, Chief Commercial Officer, Opthea. He joins the Company from Astellas where he served in commercial strategy and market access leadership roles to drive the successful launch of Izervay in geographic atrophy.